Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $26 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico reiterated an Outperform rating on Edgewise Therapeutics (NASDAQ:EWTX) and maintained a $26 price target.

April 16, 2024 | 2:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico reiterated an Outperform rating on Edgewise Therapeutics and maintained a $26 price target.
The reiteration of an Outperform rating and the maintenance of a $26 price target by a reputable analyst like Laura Chico from Wedbush suggests a strong vote of confidence in Edgewise Therapeutics. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in EWTX's stock price, reflecting the analyst's positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100